Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$331.94
+0.7%
$293.35
$205.87
$333.70
$43.28B0.23853,986 shs431,157 shs
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$56.44
$63.50
$11.52B1.152.05 million shsN/A
CureVac N.V. stock logo
CVAC
CureVac
$5.40
-0.1%
$4.41
$2.37
$5.72
$1.21B2.53786,138 shs751,012 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$9.33
$10.79
$9.20
$16.05
$4.38B0.521,337 shs2,200 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$36.33
+0.4%
$33.79
$24.05
$36.43
$20.42B0.53.69 million shs1.20 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.66%+4.30%+9.27%+40.81%+33.48%
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+12.33%
CureVac N.V. stock logo
CVAC
CureVac
-0.09%-0.09%+14.79%+108.30%+72.92%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%-10.10%-0.74%-32.97%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
+0.37%+2.99%+9.12%+16.76%+40.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.3145 of 5 stars
2.44.00.04.33.92.50.6
Catalent, Inc. stock logo
CTLT
Catalent
1.1493 of 5 stars
1.00.00.04.60.00.01.9
CureVac N.V. stock logo
CVAC
CureVac
4.6351 of 5 stars
4.15.00.04.90.90.01.3
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
4.9175 of 5 stars
3.61.03.33.74.01.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.79
Moderate Buy$340.002.43% Upside
Catalent, Inc. stock logo
CTLT
Catalent
2.00
Hold$63.500.03% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8326.66% Upside
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00
N/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.25
Buy$47.3330.31% Upside

Current Analyst Ratings Breakdown

Latest ALNY, RPRX, CVAC, CTLT, and OPHLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.00
6/26/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$320.00 ➝ $377.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/24/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.00
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/16/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$51.00
5/2/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$331.00 ➝ $349.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.25B19.25N/AN/A$0.52 per share638.35
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.09$0.87 per share6.18$3.36 per share1.61
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.20B1.37$1.08 per share8.66$11.07 per share0.84
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.26B9.02$4.21 per share8.63$17.56 per share2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A372.97N/A-11.49%-510.31%-6.48%7/30/2025 (Estimated)
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.86N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$330.31M$0.7013.33N/A10.24%6.20%4.66%7/28/2025 (Estimated)
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$858.98M$1.8519.647.471.8648.23%24.71%13.87%8/6/2025 (Estimated)

Latest ALNY, RPRX, CVAC, CTLT, and OPHLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/8/2025Q1 2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.99$1.06+$0.07$0.41$724.69 million$839.00 million
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.882.42%N/A47.57%5 Years

Latest ALNY, RPRX, CVAC, CTLT, and OPHLF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/21/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.222.7%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8.88
3.04
2.98
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.13
3.07
2.56
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.68
1.56
1.56

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Catalent, Inc. stock logo
CTLT
Catalent
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1.50%
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,230130.39 million128.43 millionOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
3,853469.71 millionN/ANot Optionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
80562.24 million455.98 millionOptionable

Recent News About These Companies

RPRX Royalty Pharma plc - Seeking Alpha
Royalty Pharma plc (RPRX) Balance Sheet - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$331.94 +2.17 (+0.66%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$331.94 0.00 (0.00%)
As of 07/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.40 -0.01 (-0.09%)
As of 07/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$9.33 0.00 (0.00%)
As of 07/2/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$36.33 +0.14 (+0.37%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$36.31 -0.02 (-0.05%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.